Results 1 to 10 of about 3,703 (241)

Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients. [PDF]

Front Med (Lausanne), 2023
ObjectiveTransfusion of HLA-matched platelets can reduce the effect of alloimmune responses on platelet transfusion efficacy; however, finding HLA-matched platelets in the population is nearly impossible. Almost all HLA-matched platelets from related are half-matched, but the hemostatic efficacy of related donor platelets is unclear.
Zhang JC, Ni LH, Tu Y, Hu HX.
europepmc   +6 more sources

Severe platelet transfusion refractoriness after thoracoabdominal aneurysm repair. [PDF]

J Vasc Surg Cases Innov Tech
Severe thrombocytopenia after thoracoabdominal aortic aneurysm repair poses a significant clinical risk in the immediate postoperative period. Understanding the mechanisms of refractoriness to platelet transfusion is relevant to supporting thrombocytopenic patients postoperatively.
Motyl CM, Phillips SD, May JE, Beck AW.
europepmc   +6 more sources

Evaluation and management of platelet transfusion refractoriness. [PDF]

Blood Res, 2022
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common
Youk HJ, Hwang SH, Oh HB, Ko DH.
europepmc   +3 more sources

Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects. [PDF]

Front Immunol, 2023
Couvidou A, Rojas-Jiménez G, Dupuis A, Maître B.   +3 more
europepmc   +3 more sources

Avatrombopag for the salvage treatment of platelet transfusion refractoriness. [PDF]

Ther Adv Hematol
Background: Platelet transfusion refractoriness (PTR) is a life-threatening and intractable condition in hematological patients. Thrombopoietin receptor agonists such as avatrombopag promote platelet production and modulate immune intolerance. However, its application in PTR has not been extensively studied. Objectives: We aimed to compare the platelet
Qin Y, Wang Y, Zhang Y, Jiao Y, Ye J.
europepmc   +4 more sources

A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management. [PDF]

Transfusion, 2022
Pedini P, Hicheri Y, Bertand G, Dettori I, Basire A, Lazaygues C, Chabrières C, Perrin C, Pascal J, Chiaroni J, Renac V, Ladaique P, Vey N, Picard C.   +13 more
europepmc   +3 more sources

Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis. [PDF]

Front Med (Lausanne), 2022
Liu Y, Zhang Y, Chen D, Fu Y.
europepmc   +2 more sources

First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report. [PDF]

World J Clin Cases, 2023
Tu SK, Fan HJ, Shi ZW, Li XL, Li M, Song K.   +5 more
europepmc   +2 more sources

A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. [PDF]

Br J Haematol, 2020
Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R.   +14 more
europepmc   +3 more sources

Development of a Calculated Panel Reactive Antibody Web Service with Local Frequencies for Platelet Transfusion Refractoriness Risk Stratification. [PDF]

J Pathol Inform, 2019
Gordon WJ, Ainsworth L, Aronson S, Baronas J, Kaufman RM, Guleria I, Milford EL, Oates M, Paz RD, Yeung MY, Lane WJ.   +10 more
europepmc   +2 more sources